| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/TPJ.2008.4 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/tpj.2008.4 |
| P698 | PubMed publication ID | 18301416 |
| P5875 | ResearchGate publication ID | 5551797 |
| P2093 | author name string | L Li | |
| A D Roses | |||
| E H Lai | |||
| M Mosteller | |||
| M R Nelson | |||
| S-A Bacanu | |||
| C E Bowman | |||
| M G Ehm | |||
| P2860 | cites work | HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol | Q24555784 |
| PLINK: a tool set for whole-genome association and population-based linkage analyses | Q24677407 | ||
| Statistical significance for genomewide studies | Q24681264 | ||
| Principal components analysis corrects for stratification in genome-wide association studies | Q27860975 | ||
| Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients | Q28169189 | ||
| Genetic variations in HLA-B region and hypersensitivity reactions to abacavir | Q28214097 | ||
| Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan | Q28249001 | ||
| Medical genetics: a marker for Stevens-Johnson syndrome | Q28254047 | ||
| A new multipoint method for genome-wide association studies by imputation of genotypes | Q29547209 | ||
| Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies | Q29616299 | ||
| Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus | Q33882066 | ||
| Risk of cardiovascular events associated with selective COX-2 inhibitors | Q34087109 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions | Q34429480 | ||
| Disease-specific target selection: a critical first step down the right road | Q36039820 | ||
| A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. | Q37161006 | ||
| Adverse drug reactions: definitions, diagnosis, and management | Q40739350 | ||
| Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis | Q44385947 | ||
| A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. | Q44675167 | ||
| Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations | Q44796890 | ||
| Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients | Q45009159 | ||
| Case-only analysis of treatment-covariate interactions in clinical trials | Q46152923 | ||
| Evaluating and improving power in whole-genome association studies using fixed marker sets. | Q53255191 | ||
| A single-nucleotide polymorphism tagging set for human drug metabolism and transport | Q57309672 | ||
| Design of Case-controls Studies with Unscreened Controls | Q58132458 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 23-33 | |
| P577 | publication date | 2008-02-26 | |
| P1433 | published in | The Pharmacogenomics Journal | Q10534704 |
| P1476 | title | Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions | |
| P478 | volume | 9 |
| Q36004460 | A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer |
| Q36380880 | A non-synonymous single nucleotide polymorphism in an OPRM1 splice variant is associated with fentanyl-induced emesis in women undergoing minor gynaecological surgery |
| Q38085220 | A review of pharmacogenetics of adverse drug reactions in elderly people |
| Q38836848 | A web resource for mining HLA associations with adverse drug reactions: HLA-ADR |
| Q36526428 | Association between GABA(A) receptor subunit gene cluster and zolpidem-induced complex sleep behaviors in Han Chinese. |
| Q36057728 | Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics |
| Q37688053 | Classical twin design in modern pharmacogenomics studies |
| Q37657540 | Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. |
| Q90256099 | Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis |
| Q43207061 | GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans |
| Q28264131 | Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy |
| Q28550088 | Genome-Wide Association Study in Immunocompetent Patients with Delayed Hypersensitivity to Sulfonamide Antimicrobials |
| Q57302671 | Genome-wide association study of serious blistering skin rash caused by drugs |
| Q35288691 | Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols |
| Q37209075 | Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility |
| Q33760652 | Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. |
| Q35908584 | Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202 |
| Q51199177 | HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions. |
| Q29417159 | HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin |
| Q44155333 | HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese |
| Q91599524 | HLA-C*12:02 is strongly associated with Xuesaitong-induced cutaneous adverse drug reactions |
| Q42554064 | How informative is a negative finding in a small pharmacogenetic study? |
| Q39802246 | Identifying patient subtypes in multiple sclerosis and tailoring immunotherapy: challenges for the future |
| Q26787099 | Impact of New Genomic Technologies on Understanding Adverse Drug Reactions |
| Q34971477 | Inherited destiny? Genetics and gestational diabetes mellitus |
| Q30927447 | Japan PGx Data Science Consortium Database: SNPs and HLA genotype data from 2994 Japanese healthy individuals for pharmacogenomics studies |
| Q37707119 | Methods for optimizing statistical analyses in pharmacogenomics research |
| Q37363157 | Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans |
| Q36117626 | Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics |
| Q34181995 | Pharmacogenetics of Anti-Diabetes Drugs |
| Q37770487 | Pharmacogenetics of drug-induced liver injury |
| Q37791154 | Pharmacogenomics and active surveillance for serious adverse drug reactions in children. |
| Q42654621 | Pharmacogenomics and bioinformatics: PharmGKB. |
| Q28274686 | Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery |
| Q34987138 | Pharmacogenomics of adverse drug reactions: practical applications and perspectives |
| Q28083100 | Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity |
| Q36915440 | The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research |
| Q36848413 | The limits of genome-wide methods for pharmacogenomic testing |
| Q30226502 | The perceptions of pharmacists in Victoria, Australia on pharmacogenetics and its implications |
| Q36441528 | The role of genetics in pre-eclampsia and potential pharmacogenomic interventions |
| Q34791981 | The use of genomic information to optimize cancer chemotherapy |
| Q44684432 | Time (again) for a randomized trial of pharmacogenetics of antiretroviral therapy |
| Q34561910 | Toxicogenetics: population-based testing of drug and chemical safety in mouse models |
Search more.